Group 1 - The core focus events for Dize Pharmaceutical in 2026 and beyond include the progress of H-share listing, key milestones in the R&D pipeline, annual business plan review, and commercialization and market expansion [1] - Dize Pharmaceutical submitted its H-share listing application to the Hong Kong Stock Exchange on January 23, 2026, aiming for a dual listing in Hong Kong to enhance its global strategy and attract international investors [2] - The company plans to advance multiple core products into clinical data update stages in 2026, including the global multi-center Phase III study of Shuwotai (Shuwotai) for EGFR Exon20ins non-small cell lung cancer, which has completed patient enrollment [3] Group 2 - Dize Pharmaceutical plans to hold a board meeting in 2026 to review the annual sales plan, which is yet to be finalized and will be disclosed after board approval [4] - The company aims to leverage the inclusion of core products Shuwotai and Guaizhe in the national medical insurance catalog to deepen domestic market coverage and promote overseas commercialization in 2026 [5] - The sales expense ratio decreased to 72% in the first three quarters of 2025, and the company plans to further enhance operational efficiency in 2026 [5]

Core Insights - The company, Dizhe Pharmaceutical, reported a strong revenue growth of 73.23% year-on-year, reaching 586 million yuan in the first three quarters of 2025, with a quarterly revenue of 231 million yuan in Q3 2025 [1] - Despite being in a research and development phase with net profits not yet positive, the strong revenue growth and improving cash flow indicate that the company has entered a new stage of product volume expansion and value realization [1] Revenue Growth Drivers - The significant revenue increase is primarily driven by two core products: Shuwozhe (Shuwotini) and Gaoruizhe (Golisib), which have been included in the national medical insurance drug list in 2024, leading to rapid sales growth [2] - Shuwozhe is the first and only domestic innovative drug approved for EGFR Exon20ins mutation non-small cell lung cancer (NSCLC) in both China and the US, marking a key milestone in the company's internationalization [2] - Gaoruizhe is the first high-selective JAK1 inhibitor approved for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) in China, filling a clinical gap in the market for nearly a decade [2] - The company has demonstrated a stable self-sustaining capability with all revenue growth coming from commercialized products, validating its business model [2] Research and Development Progress - The company maintains high R&D investment despite rapid revenue growth, with multiple competitive product pipelines in oncology, including two products already launched and two in late clinical stages [3] - Recent R&D advancements include the FDA's accelerated approval of Shuwozhe and the recognition of the dual-target inhibitor birelentinib for chronic lymphocytic leukemia/small lymphocytic lymphoma [3] - The company has over 1.9 billion yuan in cash reserves, providing solid support for ongoing R&D, clinical development, and commercialization efforts [3] Investment Outlook - Analysts believe that Dizhe Pharmaceutical has established a virtuous development pattern characterized by rapid cash flow from commercialized products, high growth expectations from innovative pipelines, and successful global market expansion of key products [4] - The investment logic is based not only on short-term growth from the domestic medical insurance market but also on the long-term global value supported by its innovative capabilities [4]